DIAMYD Aktie

 

Diamyd Medical participates in two significant events in the field of diabetes; the Critical Path Institute (C-path) Workshop: 21st Century Trials in New-Onset T1D, taking place virtually on June 17-18, and the American Diabetes Association's (ADA) 85th Scientific Sessions to be held in Chicago, US, on June 20-23. Critical Path Institute Workshop Diamyd Medical will participate in the C-Path workshop titled "21st Century Trials in New-Onset Type 1 Diabetes: How the use of C-peptide can accelerate the development of next-gen disease-modifying therapies for T1D," scheduled for June 17-18....

Niklas Axelsson has been appointed CFO of Diamyd Medical. He will assume his position in August and will also join the management team. Niklas Axelsson brings more than 25 years of experience across the pharmaceutical, biotech, and financial sectors. “With Phase 3 readout expected in less than a year, Diamyd Medical is entering a critical stage in its development”, says Ulf Hannelius, CEO of Diamyd Medical. Niklas Axelsson's proven financial leadership in both global pharma and emerging biotech makes him an ideal addition to our executive team.” "This is a particularly exciting moment to...

Following the announcement of the final outcome of Diamyd Medical AB's (publ) ("Diamyd Medical" or the "Company") rights issue carried out in April 2025, it has come to the Company's attention that, due to administrative reasons, one subscription application was not included in the final outcome. As a result, an adjustment has been necessary. After this adjustment, the number of subscribed A-units in the rights issue amounts to 514,624 and the number of subscribed B-units amounts to 27,686,603. Consequently, this means that the number of B-units issued within the framework of the additional...

THIS PRESS RELEASE MAY NOT BE RELEASED, PUBLICATED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONGKONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTION IN WHOLE OR IN PART, IS SUBJECT TO LEGAL RESTRICTIONS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER, OR A SOLICITATION OF ANY OFFER, TO BUY OR SUBSCRIBE FOR ANY SECURITIES IN DIAMYD MEDICAL AB (PUBL) IN ANY JURISDICTION. PLEASE REFER TO THE “IMPORTANT INFORMATION” SECTION BELOW. Diamyd Medical AB (“Diamyd Medical” or the...

THIS PRESS RELEASE MAY NOT BE RELEASED, PUBLICATED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONGKONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTION IN WHOLE OR IN PART, IS SUBJECT TO LEGAL RESTRICTIONS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER, OR A SOLICITATION OF ANY OFFER, TO BUY OR SUBSCRIBE FOR ANY SECURITIES IN DIAMYD MEDICAL AB (PUBL) IN ANY JURISDICTION. PLEASE REFER TO THE “IMPORTANT INFORMATION” SECTION BELOW. On April 30, 2025, Diamyd Medical AB (publ)...

THIS PRESS RELEASE MAY NOT BE RELEASED, PUBLICATED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONGKONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTION IN WHOLE OR IN PART, IS SUBJECT TO LEGAL RESTRICTIONS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER, OR A SOLICITATION OF ANY OFFER, TO BUY OR SUBSCRIBE FOR ANY SECURITIES IN DIAMYD MEDICAL AB (PUBL) IN ANY JURISDICTION. PLEASE REFER TO THE “IMPORTANT INFORMATION” SECTION BELOW. Diamyd Medical AB (publ) (“Diamyd Medical”...

THIS PRESS RELEASE MAY NOT BE RELEASED, PUBLICATED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONGKONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTION IN WHOLE OR IN PART, IS SUBJECT TO LEGAL RESTRICTIONS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER, OR A SOLICITATION OF ANY OFFER, TO BUY OR SUBSCRIBE FOR ANY SECURITIES IN DIAMYD MEDICAL AB (PUBL) IN ANY JURISDICTION. PLEASE REFER TO THE “IMPORTANT INFORMATION” SECTION BELOW. Diamyd Medical AB (publ) (“Diamyd Medical”...

Tomorrow, Tuesday, April 29, 2025, is the last day to subscribe for participation in Diamyd Medical AB's (publ) ("Diamyd Medical" or the "Company") rights issue of up to approximately SEK 208 million. The rights issue is covered by subscription commitments and subscription intentions equivalent to SEK 52.1 million, corresponding to 25 percent of the rights issue. No fee is to be paid for the subscription commitments and subscription intentions. The subscription period for Diamyd Medical's rights issue runs from and including April 15 to and including tomorrow, Tuesday, April 29, 2025....

The European Patent Office (EPO) has informed Diamyd Medical that the patent application protecting the use of insulin-based antigens for the treatment of autoimmune diabetes in patients carrying the HLA DR4-DQ8 genetic marker will be granted. The patent, valid until 2035, marks an important step in advancing precision medicine for diabetes care. The forthcoming EPO patent grant builds on the foundation already established for patients with the HLA DR3-DQ2 genotype, a distinct genetic subgroup currently targeted by Diamyd Medical's GAD-specific immunotherapy Diamyd[®] in the ongoing Phase 3...

The independent Data Safety Monitoring Board (DSMB) has completed its fifth scheduled safety review of Diamyd Medical's registrational Phase 3 trial, DIAGNODE-3, evaluating the precision medicine immunotherapy Diamyd[®]. The review identified no safety concerns and resulted in a recommendation to continue the trial as planned. DIAGNODE-3 is conducted under Fast Track and Orphan Drug Designations granted by the U.S. Food and Drug Administration (FDA), with an agreement in place that an early efficacy readout planned for March 2026 may serve as the basis for a Biologics License Application (...

Chairman of the Board, Anders Essen-Möller, is increasing his commitment by SEK 1 million to a total of SEK 6 million. All members of the management team are subscribing for their pro rata share. In total, the rights issue is covered by subscription commitments and subscription intentions amounting to approximately SEK 47.4 million, corresponding to approximately 22.8 percent of the rights issue. The subscription period for Diamyd Medical's rights issue runs from April 15 to April 29, 2025. It is also possible to subscribe for units without preferential rights. Allotment of units for...

STOCKHOLM, April 21, 2025 /PRNewswire/ -- In a recent investor interview, Diamyd Medical Board Member Professor Mark Atkinson and CEO Ulf Hannelius shared key insights into the Company's positioning as a first-mover in precision medicine-based, disease-modifying and preventive treatment......

The Australian Patent Office has granted a patent protecting a novel immunotherapeutic composition developed by Diamyd Medical for use in the treatment and prevention of autoimmune diabetes. The patent, valid until 2035, covers a composition comprising the antigens glutamic acid decarboxylase (GAD) and proinsulin immobilized on separate carrier particles. “This patent expands our precision medicine platform for autoimmune diabetes and reinforces the intellectual property protection around our immunotherapeutic technologies,” says Anton Lindqvist, Chief Scientific Officer of Diamyd Medical. “...

THIS PRESS RELEASE MAY NOT BE RELEASED, PUBLICATED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONGKONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTION IN WHOLE OR IN PART, IS SUBJECT TO LEGAL RESTRICTIONS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER, OR A SOLICITATION OF ANY OFFER, TO BUY OR SUBSCRIBE FOR ANY SECURITIES IN DIAMYD MEDICAL AB (PUBL) IN ANY JURISDICTION. PLEASE REFER TO THE “IMPORTANT INFORMATION” SECTION BELOW. The prospectus with regards to Diamyd...

Diamyd Medical today announces in its second quarterly report for fiscal year 2024/2025 continued progress toward a transformative regulatory milestone, with early Phase 3 results from the DIAGNODE-3 trial expected in March 2026. The trial is on track for full enrollment in 2025, alongside planned GMP certification of the Company's biomanufacturing facility in Umeå. Following internal strategic discussions and input from its Scientific Advisory Board, Diamyd Medical is also expanding its precision medicine platform and evaluating the inclusion of the LADA (Latent Autoimmune Diabetes in Adults)...

An investor consortium led by Patrik Hansen has submitted subscription commitments totaling SEK 21.0 million for the upcoming rights issue announced on February 28, 2025. In total, the rights issue of subscription commitments and subscription intentions of approximately SEK 38.7 million, corresponding to approximately 18.6 percent of the rights issue, is thus covered. As previously announced, a group of existing shareholders in the Company have submitted subscription commitments totaling approximately SEK 9.8 million. Chairman of the Board and founder Anders Essen-Möller has undertaken to...

Process validation, stability studies and other activities for GMP production of the active pharmaceutical ingredient GAD65 are ongoing to finalize all aspects regarding manufacturing, which is required for submitting a Biologics Licensing Application (BLA) for the Company's investigational medicine Diamyd[®]. Full-scale technical batches of GAD65 have been produced at the wholly owned biopharmaceutical manufacturing facility in Umeå. Active pharmaceutical ingredient (API) has thereafter been formulated into Diamyd[®] and dispensed into vials by an external Contract Development and...

Diamyd Medical will present analyses of clinical data from trials in Type 1 Diabetes evaluating the investigational precision immunotherapy Diamyd[®] (rhGAD65/alum) at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Amsterdam, the Netherlands. The analyses, highlighting significant correlation between C-peptide secretion and glycemic benefits in Type 1 Diabetes, are part of the ongoing preparations ahead of Diamyd Medical's Phase 3 readout expected around March 2026 where C-peptide will serve as the primary endpoint to support a potential accelerated Biologics License...

Diamyd Medical, in collaboration with Mainly AI and ASSET partners, highlights meaningful progress in AI-driven screening and risk prediction for Type 1 Diabetes at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Amsterdam (March 19–22, 2025). Dr. Gun Forsander (Institute for Clinical Sciences, Sahlgrenska Academy) will present the findings at an invited presentation at the industry symposium sponsored by Sanofi: BRIDGE TO THE FUTURE, Exploring How Innovation Can Evolve the Early Detection and Management of T1D. “Screening of Type 1 Diabetes has become a hot topic...

THIS PRESS RELEASE MAY NOT BE RELEASED, PUBLICATED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONGKONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTION IN WHOLE OR IN PART, IS SUBJECT TO LEGAL RESTRICTIONS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER, OR A SOLICITATION OF ANY OFFER, TO BUY OR SUBSCRIBE FOR ANY SECURITIES IN DIAMYD MEDICAL AB (PUBL) IN ANY JURISDICTION. PLEASE REFER TO THE “IMPORTANT INFORMATION” SECTION BELOW. Diamyd Medical announces that a group of...